Skip Navigation
Close

8 Results

Acute Lymphocytic Leukemia with Novartis Kymriah, Adult
Kymriah, developed by Novartis, is a type of immunotherapy for young adult patients (up to 25 years of age) with Acute Lymphocytic Leukemia (ALL). Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Acute Lymphocytic Leukemia with Novartis Kymriah, Pediatric
Kymriah, developed by Novartis, is a type of immunotherapy for pediatric patients with Acute Lymphocytic Leukemia (ALL). Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
B-Cell Lymphoma with Kite Yescarta, Adult
Yescarta, developed by Kite, is a type of immunotherapy for young adult patients (up to 25 years of age) with B-Cell Lymphoma. Through Yescarta therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
B-Cell Lymphoma with Novartis Kymriah, Adult
Kymriah, developed by Novartis, is a type of immunotherapy for young adults (up to 25 years of age) with B-Cell Lymphoma. Through Kymriah therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
B-Cell Lymphoma with Novartis Kymriah, Pediatric
Kymriah, developed by Novartis, is a type of immunotherapy for pediatric patients with B-Cell Lymphoma. Through Kymriah therapy, a patient's T-cells are genertically reprogrammed to fight cancer cells.
Large B-Cell Lymphoma with Juno Breyanzi
Breyanzi, developed by Juno Technologies, is a type of immunotherapy for adult patients with Large B-cell Lymphoma. Through Breyanzi therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Mantel Cell Lymphoma with Kite Tecartus, Adult
Tecartus, developed by Kite, is a type of immunotherapy for adult patients with Mantel Cell Lymphoma. Through Tecartus therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.
Multiple Myeloma with Bluebird Abecma
Abecma, developed by Bluebird bio, is a type of immunotherapy for adult patients with Multiple Myeloma. Through Abecma therapy, a patient's T-cells are genetically reprogrammed to fight cancer cells.